Revolution Medicines
D

RVMD

172.280
USD
-4.01
(-2.27%)
Post Trading·172.020USD-0.260(-0.15%)
Last updated: · Delayed 15 min
Q4 FY2026 · Earnings report
EPS estimate -1.22Revenue estimate 388.66M
OverviewFinancialsForecastEarningsCompany

Revolution Medicines executives and insider trading

Mark A. Goldsmith sold 291,273 shares for 34.61M USD in 22 sales over the last twelve months, the last on 16 September 2026, and bought none on the open market.

Over the last twelve months Revolution Medicines's insiders sold 933,285 shares for 139.13M USD in 149 sales on the open market, and bought 0 shares in 0 purchases.

Insiders over the last twelve months

Insider sales
149
Shares sold
933,285
Value sold
139.13M USD
Insider purchases
0

Insiders buying against selling

Bought on the market
Sold on the market
0
1 week
6.89M USD
0
1 month
7.32M USD
0
3 months
67.34M USD
0
6 months
91.83M USD
0
1 year
139.13M USD
60.00M USD
2 years
155.52M USD
Sold, decided at the timeSold under a Rule 10b5-1 plan set in advance

Open-market purchases and sales reported on Form 4, by value. Awards, option exercises and shares withheld for tax are not counted. Whether a sale was under a Rule 10b5-1 plan is read from each Form 4 at the SEC (the box exists on filings since April 2023).

Executives and directors

The people who run the company and the directors who reported trades, with what each bought and sold on the open market over the last twelve months. The CEO first, then whoever traded most.

NamePositionAgeShares sold (12 months)Value sold (12 months)Shares bought (12 months)Last saleShares held after
Mark A. Goldsmith CEOChief Executive Officer, President & Chairman64291,27334.61M USD—16 Sept 2026267,117
Margaret A. Horn Chief Operating Officer63189,39725.25M USD—16 Sept 2026154,571
Stephen Michael Kelsey See Remarks—112,02421.33M USD—16 Sept 2026291,791
Lorence H. Kim Director—73,09014.97M USD—8 Sept 202616,384
Jeff Cislini Senior Vice President, General Counsel & Corporate Secretary5183,12414.61M USD—25 Sept 202651,776
Jack Anders Chief Financial Officer4983,80013.22M USD—11 Nov 2026154,966
Anthony Mancini See Remarks—74,12110.39M USD—9 Nov 202640,576
Elizabeth M Anderson Director—10,1431.96M USD—22 Sept 202614,476
Alan B. Sandler Chief Development Officer—6,6501.34M USD—29 Sept 202658,868
Sushil Patel Director—5,5801.05M USD—29 Jun 202627,236
Lin Wei Chief Medical Officer—2,073206.22K USD—17 Mar 2026101,366
Xiaolin Wang See Remarks—2,010199.96K USD—17 Mar 2026116,063

Insider sales and purchases by quarter

How many insider sales and purchases were reported each quarter.

Insider sales Insider purchases

Every insider transaction

Insiders must report every trade in the company's shares to the SEC within two business days, on Form 4. Only purchases and sales are trades on the open market; awards, option exercises, shares withheld for tax and gifts come with pay, and the twelve-month totals leave them out.

DateNameTransactionSharesPriceValueShares held afterFiling
11 Nov 2026Jack AndersSale3,499181.04633.47K USD151,467Form 4
11 Nov 2026Jack AndersSale5,776182.091.05M USD145,691Form 4
11 Nov 2026Jack AndersSale2,700182.87493.75K USD142,991Form 4
11 Nov 2026Jack AndersSale1,900184.02349.65K USD141,091Form 4
11 Nov 2026Jack AndersSale800185.04148.03K USD140,291Form 4
11 Nov 2026Jack AndersSale400186.4174.57K USD139,891Form 4
11 Nov 2026Jack AndersSale600187.34112.40K USD139,291Form 4
11 Nov 2026Jack AndersSale200189.1737.83K USD139,091Form 4
11 Nov 2026Jack AndersSale500190.9995.50K USD138,591Form 4
11 Nov 2026Jack AndersSale9,486191.941.82M USD129,105Form 4
11 Nov 2026Jack AndersSale9,889192.841.91M USD119,216Form 4
9 Nov 2026Anthony ManciniSale811200.00162.20K USD39,765Form 4
26 Oct 2026Anthony ManciniSale2,310186.99431.95K USD39,765Form 4
29 Sept 2026Alan B. SandlerSale2,200200.82441.80K USD56,668Form 4
29 Sept 2026Alan B. SandlerSale1,609201.72324.57K USD55,059Form 4

Common questions about Revolution Medicines's executives and insiders

Source: Financial Modeling PrepVerified against SEC filings